ArticleFrontiers in public health2022
Impact of socioeconomic status on cancer staging, survival in non-small cell lung cancer.
Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 7 citations in OpenAlex.
- Development and internal validation of a prognostic model for cancer-specific survival in elderly patients with metastatic non-small cell lung cancer: a SEER-based study.Journal of thoracic disease · 2026Article
- Impact of socioeconomic determinants and clinical characteristics on non-small cell lung cancer survival: a real-world cohort study.Journal of thoracic disease · 2026Article
- Association of ZIP code sociodemographic characteristics with radiation oncology services, payments, and technique utilization.Frontiers in oncology · 2026Article
- Molecular testing, first-line treatment patterns, and survival in metastatic Colombian non-small cell lung cancer: the RECAPC multicenter registry.Frontiers in oncology · 2026Article
- Mediators of Racial Inequities in Non-Small Cell Lung Cancer Care.Cancer medicine · 2025Article
- Racialized economic segregation and disparities in non-small cell lung cancer care and outcomes.CHEST pulmonary · 2025Article
- Small Cell Lung Cancer and Pleural Effusion: An Analysis from a District General Hospital.Pulmonary therapy · 2023Article
- Smoking status and the association between patient-level factors and survival among lung cancer patients.Journal of the National Cancer Institute · 2023Article
- Survival of bronchopulmonary cancers according to radon exposure.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We performed this study to evaluate the association of socioeconomic status (SES) factors with cancer-specific survival (CSS) of patients with non-small cell lung cancer (NSCLC). We further assessed the predictive value of a novel Tumor Node Metastasis (TNM)-SES staging system, combining the TNM stage with the SES stage. Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database, we selected 40,378 patients diagnosed with NSCLC from 2012 to 2016. Cox regression method and Harrell's concordance index (C-index) were performed to select the SES factors related to CSS and evaluate the predictive ability of the novel TNM-SES stage. We used Kaplan-Meier curves and a log-rank test to conduct a survival analysis. Results: We identified four SES factors (marriage, insurance, education, and household income) associated with CSS and constructed the SES stage (SES-1 and SES-2). NSCLC patients with SES-2 stage (low SES) was associated with young adult, black race, male, squamous carcinoma, upper lobe site, and advanced stage. SES-2 stage patients were significantly associated with a dismal prognosis of patients with NSCLC, with a 21.0% increased risk (HR = 1.21, 95%CI (1.18-1.24), Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.